Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

Core Insights - Tarsus Pharmaceuticals has launched a direct-to-consumer TV campaign for XDEMVY, the first FDA-approved treatment for Demodex blepharitis, which affects approximately 25 million people in the U.S. [1][4][7] Group 1: Campaign Overview - The campaign titled "Your Mitey Problem" creatively illustrates the impact of Demodex mites on patients' eyelids, showcasing a 'party' of mites causing irritation and inflammation [3][4] - The campaign aims to educate patients about Demodex blepharitis and encourage them to consult eye care providers regarding XDEMVY [4][5] - The multi-channel campaign is currently live on connected TV devices, streaming channels, and includes digital and social media components [5] Group 2: Product Information - XDEMVY (lotilaner ophthalmic solution) 0.25% is designed to target and eradicate Demodex mites, addressing the root cause of Demodex blepharitis [8] - The active ingredient, lotilaner, selectively inhibits GABA-Cl channels, effectively eradicating the mites [8] - Clinical trials involving over 800 patients demonstrated that XDEMVY met primary and secondary endpoints with no serious treatment-related adverse events [8][10] Group 3: Company Background - Tarsus Pharmaceuticals focuses on unmet medical needs, particularly in eye care, and is advancing a pipeline that includes treatments for various diseases [9] - The company is also investigating additional products for conditions such as Meibomian Gland Disease and Rosacea, all currently in Phase 2 trials [9]